Navigation Links
Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune,Deficiency

THE WOODLANDS, Texas, June 08, 2007 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. today announced the publication of new findings from a joint research project with scientists at Fox Chase Cancer Center in Philadelphia, PA. Together with David L. Wiest, Ph.D., Lexicon researchers have discovered a novel and surprising role for ribosomal protein L22 (Rpl22) in the development of T lymphocytes. These findings have been published in the June issue of the journal Immunity.

Dr. Wiest and scientists at Lexicon Pharmaceuticals discovered that deletion of the ubiquitously expressed Rpl22 gene resulted in the up-regulation of p53, a key tumor suppressor gene that triggers apoptosis and cell death. Further, it was determined that this up-regulation of p53 was responsible for blocking alpha-beta+ T cell development thereby creating an immune-deficient state.

"The connection between Rpl22 and the p53-mediated apoptosis pathway is very exciting," said Dr. David Wiest, Member, Basic Science Division at Fox Chase Cancer Center. "If research confirms our theories, Rpl22 may prove to be an important biomarker for certain T cell immune deficiency diseases and some types of lymphoid cancers."

Rpl22 is one of several proteins that comprise the large subunit of eukaryotic ribosomes, cellular complexes that are responsible for translating messenger RNA and assembling proteins. Although not-required for translation, Rpl22 may play a role in protein synthesis or macromolecular assembly that is important for some cell types, but not others.

"These findings could help us to further define the pathways involved in T lymphocyte development and regulation," said Dr. Tamas Oravecz, Lexicon's Vice President of Immunology and Oncology. "While Rp122 will likely prove difficult for development as a classic drug target, understanding its role could contribute significantly to its potential as a biomarker for disease."

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome and cognitive disorders. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc., N.V. Organon and Takeda Pharmaceutical Company Limited. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.

    Editor's Note:

    1.  The article, "Ablation of Ribosomal Protein L22 Selectively Impairs

        alpha-beta T Cell Development by Activation of a p53-Dependent

        Checkpoint" may be obtained with a subscription at

        http://www.immunity.com/content/current.

    2.  For more information on Dr. David Wiest, please visit Fox Chase Cancer

        Center's website at http://www.fccc.edu or Dr. Wiest's research page

        at http://www.fccc.edu/research/pid/wiest.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellect ual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Bobbie Faulkner, Manager, Investor Relations of LexiconPharmaceuticals, Inc., +1-281-863-3503, bfaulkner@lexpharma.com

Web site: http://www.lexpharma.com/

Ticker Symbol: (NASDAQ-NMS:LXRX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
2. Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. ... big data solutions, today announced that its MyDario product is expected to ... TV listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, ... ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
Breaking Medicine Technology:
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
Breaking Medicine News(10 mins):